Salicylic Acid-grafted Chitosan Oligosaccharide Nanoparticle for Paclitaxel Delivery

• Published in: Journal of bioactive and compatible polymers Vol. 25; no. 3; pp. 319 - 335
• Main Authors: Wei, Xiao-Hong, Niu, Yang-Ping, Xu, Yang-Yan, Du, Yong-Zhong, Hu, Fu-Qiang, Hong Yuan
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01-05-2010; Sage Publications
• Subjects: Applied sciences; Biological and medical sciences; Exact sciences and technology; General pharmacology; Medical sciences; Natural polymers; Pharmaceutical technology. Pharmaceutical industry; Pharmacology. Drug treatments; Physicochemistry of polymers; Starch and polysaccharides; chitosan; paclitaxel; hydrotropy; controlled delivery; nanoparticle; salicylic acid; paclitaxel delivery; Biological properties; Antineoplastic agent; Particle size; Nanoparticle; Cytotoxicity; Drug carrier; Oligomer; Amidation; Paclitaxel; Electrokinetic potential; Release; Amphiphilic polymer; Salicylic acid; Control release polymer; Experimental study; In vitro; Chemical modification; Chitosan derivatives; Preparation; Oside polymer; Chitosan; Kinetics
• ISSN: 0883-9115; 1530-8030
• DOI: 10.1177/0883911510363548

A hydrotropic agent, salicylic acid (SA), was grafted to chitosan oligosaccharide (CSO) backbone to develop a CSO/SA conjugate. The CSO/SA self-assembled to form nanoparticles (NPs) in aqueous medium. The sizes of the NPs were smaller as more SA was grafted and when lower molecular weight CSO was used. The ζ-potentials of all CSO/SA NPs were above 40 mV. The critical aggregation concentrations of NPs decreased from 454.79 to 164.0 μg/mL by increasing the grafted SA content or the CSO Mw. Paclitaxel (PTX)-loaded NPs were prepared by a dialysis method; the particle sizes and ζ-potentials were smaller than the blank NPs. A series of PTX-loaded CSO28,000/SA50% NPs were prepared; as the size decreased or the drug content increased, the in vitro release rate increased. The in vitro cytotoxicity of blank CSO/SA NPs was determined using the MCF-7 cell line. The CSO/SA provides a new means of making a stable delivery for PTX.